Bioantibody Biotechnology Co., Ltd, a Nanjing-based in vitro diagnostics (IVD) and biologic company, has reportedly raised close to RMB 100 million (USD 14.8 million) in a Series A financing round. The funding was led by FangFund, with contributions from Nanjing New Industry Investment Capital, Guoqian Venture Investment Management, and Bondshine Capital. The proceeds will be used to expand the company’s diagnostic capabilities and further develop its innovative antigen and antibody raw materials.
Company Overview and Achievements
Founded in 2019, Bioantibody Bio has quickly established itself as a leader in the IVD and biologic space. The company boasts self-developed antigen and antibody raw materials, with over 60 diagnostic targets and more than 1,200 clients. This robust client base and extensive diagnostic portfolio underscore Bioantibody Bio’s commitment to innovation and quality in diagnostic solutions.
Future Outlook
The Series A financing round positions Bioantibody Bio to accelerate its growth and expand its market reach. With strong financial backing and a proven track record in developing high-quality diagnostic materials, the company is poised to make a significant impact in the global IVD market. The funding will support the development of new diagnostic targets and enhance the company’s ability to meet the growing demand for reliable and innovative diagnostic tools.-Fineline Info & Tech
